Overview

A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer

Status:
Recruiting
Trial end date:
2025-09-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety of the study drug, RP-3500 when given in combination with palliative external beam radiotherapy (EBRT) to people who have metastatic solid tumor cancer with a mutation of the ATM gene. The study researchers will do tests to find the highest dose of RP3500 that causes few or mild side effects.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborator:
Repare Therapeutics